Apr 23, 2024 Jay Jackson Sponsored Post

California and NYC Order Mandatory COVID-19 Testing Among Municipal Workers

 

New COVID-19 cases continue to surge throughout the United States, causing municipal governments to spring into action to combat the rising number of the highly infectious Delta variant cases. On Monday, California and New York City announced that they would require all government employees to get the coronavirus vaccine or face weekly COVID-19 testing. The White House also revealed that it would not be lifting international travel restrictions or re-opening US land borders to help combat the rising cases. With no clear end in sight to the ongoing pandemic, companies like Sixth Wave Innovations (CSE:SIXW) (OTCQB:SIXWF), Tonix Pharmaceuticals Holdings (NASDAQ:TNXP), Vaxart (NASDAQ:VXRT), Cocrystal Pharma Inc. (NASDAQ:COCP) and Altimune (NASDAQ:ALT) are developing rapid tests and potential treatments to combat the virus.

Development-stage nanotechnology company Sixth Wave Innovations (CSE:SIXW) (OTCQB:SIXWF) announced an update on the NSERC-sponsored grant titled: Point-of-need Microfluidic Biosensor for Detecting Airborne Viruses using Molecularly Imprinted polymers: Towards COVID-19 Virus Monitoring. The goal of the grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) is to develop a portable, low-cost technology for fast on-site air sampling and detection of droplet-encapsulated and aerosol viruses both indoors and outdoors. 

Sixth Wave is collaborating with York University and the Centre Technologique des Residus Industriels (CTRI) on the project, which began August 1, 2020. The project has focused on designing prototypes for the Sixth Wave’s Accelerated Molecular Imprinted Polymers (AMIPs) technology to detect pathogens in the air, water, and wastewater. The collaboration is part of the company’s R&D efforts to transform virus detection by testing individual patients and monitoring entire populations by detecting pathogens in HVAC systems and municipal wastewater facilities. 

The AMIP virus detection technology is based on Sixth Wave’s Molecular Imprinted Polymers, a technology that offers strategic advantages over traditional diagnostic technologies. The NSERC project has helped in advancing the capabilities of the company’s AMIP technology. 

Sixth Wave is applying its expertise in MIP technologies to bring innovative products that address the shortcomings of traditional technologies that have become more apparent with the ongoing COVID-19 pandemic.

In June, Sixth Wave revealed that its patent-pending Accelerated Molecular Imprinted Polymers (AMIPs) technology had successfully detected both the UK variant and the South African variant of SARS-CoV-2 using two independent techniques: a color-based sensor and independently verified on a Quartz Crystal Microbalance (QCM) based AMIP sensor. 

“The flexibility and robustness of the AMIPs platform was demonstrated again. These preliminary results give evidence to the claims that AMIP technology is resistant to loss of efficacy due to virus mutation and new variants. By imprinting and detecting the whole virus AMIPs can be highly resistant to virus mutation compared to other technologies such as immunoassay-based techniques that use antibodies which bind a small region of the virus spike protein. This technology has the potential to give healthcare workers peace of mind that the testing protocol they are using isn’t outdated and obsolete in the world of rapidly evolving viruses.”

Pharma’s Efforts in Ending the COVID-19 Crisis

Clinical-stage biopharmaceutical company Tonix Pharmaceuticals Holdings (NASDAQ:TNXP) announced that it signed a Purchase and Sale Agreement to acquire about 48,000 square foot R&D facility in Frederick, MD to support the company’s expanding infectious disease pipeline. The infectious disease pipeline includes TNX-1800, a live-replicating viral vaccine designed to protect against COVID 19, and TNX-3500, a small-molecule antiviral designed to prevent the replication of SARS-CoV-2. Tonix will purchase the facility from Southern Research, a partner in the development of TNX-1800 and TNX-801. The company expects to expand its R&D capabilities to increase its pipeline of vaccines and antiviral therapies especially considering the new threat of new COVID-19 variants that are exposing the shortcomings of the country’s infectious disease R&D.

Vaxart (NASDAQ:VXRT) is a clinical-stage biopharmaceutical company that is participating in the research and development of oral recombinant vaccines for COVID-19 administered by tablet rather than injection. As part of its efforts, it conducted a Phase I COVID-19 trial and released data suggesting broad cross-reactivity against other coronaviruses. Vaxart released data indicating that its first COVID-19 oral vaccine, VXA-CoV2-1 triggers mucosal immunity and includes the S and N SARS-CoV-2 proteins. The data from the Phase I trial indicated substantial CD8+ T-cell responses measured by IFN-g and TNF-a induction. The data was compared to T-cell responses from volunteers who were vaccinated with the Moderna or Pfizer mRNA vaccines, which showed fewer T-cell responses. 

The clinical-stage biotechnology company Cocrystal Pharma Inc. (NASDAQ:COCP) announced that its lead preclinical SARS-CoV-2 3CL protease inhibitor CDI-45205 is active against SARS-CoV-2 and two prominent SARS-CoV-2 variants. Cocrystal contracted a third-party laboratory to conduct in-vitro studies evaluating the antiviral activity of CDI-45205 and its analogs in VeroE6-eGFP cells infected with the Wuhan Variant (SARS-CoV-2), the UK variant, and the South African Variant. From the studies, the COVID-19 antiviral showed excellent antiviral activity against the variants. In addition to these studies, Cocrystal is also investigating broad-spectrum oral protease inhibitors and replication inhibitors for treating COVID-19. 

Altimmune (NASDAQ:ALT) a clinical-stage biopharmaceutical company released an update on its AdCOVID investigational vaccine for the prevention of COVID-19 and its T-COVID phase 1 /2 clinical trial to investigate the potential of T-COVID in preventing clinical worsening in patients with early COVID-19. In the AdCOVID update, the company reported that AdCOVID showed a substantially lower immune response compared to vaccines approved for emergency use, therefore, the company is discontinuing further development of AdCOVID beyond the completion of the Phase 1 trial. The company also discontinued enrollment for its third cohort in the Phase 1 /2 clinical trial for T-COVID, after vaccine rollout limited the number of patients qualifying for the trial.  

As the US continues to deal with increasing COVID-19 variant cases, companies like Sixth Wave Innovations are intensifying their efforts to provide vaccines and therapies to protect against the deadly virus. 

For more information about Sixth Wave Innovations (CSE:SIXW) (OTCQB:SIXWF) click here. 

Offering Cannabis, Mining and Healthcare Companies Simple, Proven Solutions For Their Largest Problems! Get the Latest News & Updates Right to Your Inbox!

Please See Disclaimer


Disclosure:

1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.

2) The Article was issued on behalf of and sponsored by, Sixth Wave Innovations Inc. Market Jar Media Inc. has or expects to receive from Sixth Wave Innovations Inc’s Digital Marketing Agency of Record (Native Ads Inc.) two hundred twenty-eight thousand six hundred USD for 26 days (19 business days).

3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on MicroSmallCap.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on MicroSmallCap.com.

5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.

6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Sixth Wave Innovations Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Sixth Wave Innovations Inc.’s industry; (b) market opportunity; (c) Sixth Wave Innovations Inc.s business plans and strategies; (d) services that Sixth Wave Innovations Inc. intends to offer; (e) Sixth Wave Innovations Inc.’s milestone projections and targets; (f) Sixth Wave Innovations Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Sixth Wave Innovations Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Sixth Wave Innovations Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Sixth Wave Innovations Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Sixth Wave Innovations Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Sixth Wave Innovations Inc.’s ability to enter into contractual arrangements with additional Pharmacies; (e) the accuracy of budgeted costs and expenditures; (f) Sixth Wave Innovations Inc.’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Sixth Wave Innovations Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Sixth Wave Innovations Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Sixth Wave Innovations Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Sixth Wave Innovations Inc.’s business operations (e) Sixth Wave Innovations Inc. may be unable to implement its growth strategy; and (f) increased competition.

Except as required by law, Sixth Wave Innovations Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Sixth Wave Innovations Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Sixth Wave Innovations Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document.

7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Sixth Wave Innovations Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Sixth Wave Innovations Inc. or such entities and are not necessarily indicative of future performance of Sixth Wave Innovations Inc. or such entities.